NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Center for Substance Abuse Treatment. Treatment for HIV-Infected Alcohol and Other Drug Abusers. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1995. (Treatment Improvement Protocol (TIP) Series, No. 15.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Treatment for HIV-Infected Alcohol and Other Drug Abusers

Treatment for HIV-Infected Alcohol and Other Drug Abusers.

Show details

Appendix A -- Bibliography

  1. Aboulker, J.P., and Swart, A.M. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee (letter) Lancet. 1993;341(8849):889–890. [PubMed: 8096582]
  2. Abrams, D.I., Goldman, A.I., Launer, C., Korvick, J.A., et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. New England Journal of Medicine. 1994;330(10):657–662. [PubMed: 7906384]
  3. Advisory Group on HIV Early Intervention. Human immunodeficiency virus early intervention physician guidelines. Archives of Family Medicine. 1994;3(11):988–1002. [PubMed: 7804482]
  4. Agency for Health Care Policy and Research. Managing early HIV infection. Early HIV Infection Guideline Panel. American Family Physician. 1994;49(4):801–814. [PubMed: 8116515]
  5. American Academy of Neurology, AIDS Task Force. Criteria for diagnosis of HIV-1 associated dementia complex: nomenclature and research case definitions for neurologic manifestations of HIV-1 infection. Neurology. 1991; 41:778-784 [PubMed: 2046917]
  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-IV. Washington, D.C.: American Psychiatric Association. 1994.
  7. American Society of Addiction Medicine. AIDS Guidelines for Facilities. Washington, D.C.: American Society of Addiction Medicine. 1991.
  8. Avins, A.L., Woods, W.J., Lindan, C.P., Hudes, E.S., et al. HIV infection and risk behaviors among heterosexuals in alcohol treatment programs. Journal of the American Medical Association. 1994;271(7):515–518. [PubMed: 8301765]
  9. Ball, J.C., Lange, W.R., Myers, C.P., and Friedman S.R. Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behavior. 1988;29(3):214–226. [PubMed: 3241064]
  10. Barnes, P.F., Bloch, A.B., Davidson, P.T., and Snider, D.E., Jr. Tuberculosis in patients with human immunodeficiency virus infection. New England Journal of Medicine. 1991;324(23):1644–1650. [PubMed: 2030721]
  11. Bass, J.B., Jr., Farer, L.S., Hopewell, P.C., O'Brien, R., et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. American Journal of Respiratory and Critical Care Medicine. 1994;149(5):1359–1374. [PubMed: 8173779]
  12. Batki, S.L., London, J., Ferrando, S.J., Pattillo, J., et al. Psychiatric disorders and drug use in 100 HIV-infected IVDUs. In: Harris, L.S., ed. Problems of Drug Dependence 1991: Proceeding of the 53rd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph 119. DHHS Publication No. (ADM) 92-1888. Rockville, Maryland: National Institute on Drug Abuse. 1992. pp. –.
  13. Batki, S.L., and London, J. 1991. Drug abuse treatment for HIV-infected patients; In: Sorensen, J.L., Wermouth, L.A., Gibson, D.R., Choi, K.-H., et al, eds. Preventing AIDS in Drug Users and Their Sexual Partners. New York: Guilford Press; pp. pp. 77–98.
  14. Batki, S.L. Buspirone in drug users with AIDS or AIDS-related complex. Journal of Clinical Psychopharmacology. 1990a; 10(3 Suppl.):111S-115S [PubMed: 2376626]
  15. Batki, S.L. Drug abuse, psychiatric disorders, and AIDS. Dual and triple diagnosis. Western Journal of Medicine (Special issue on addiction medicine) 1990b;152(5):547–552. [PMC free article: PMC1002409] [PubMed: 2190423]
  16. Batki, S.L. Treatment of intravenous drug users with AIDS: the role of methadone maintenance. Journal of Psychoactive Drugs. 1988;20(2):213–216. [PubMed: 3418453]
  17. Batki, S.L., Sorenson, Sorensen, J.L., Faltz, B., and Madover, S. Psychiatric aspects of treatment of i.v. drug abusers with AIDS. Hospital and Community Psychiatry. 1988;39(4):439–441. [PubMed: 3371914]
  18. Beck, A.T. Beck Depression Inventory. San Antonio, Texas: Psychological Corporation. 1993.
  19. Boccellari, A.A., Dilley, J.W., Chambers, D.B., Yingling, C.D., et al. Immune function and neuropsychological performance in HIV-1-infected homosexual men. Journal of Acquired Immune Deficiency Syndrome. 1993a;6(6):592–601. [PubMed: 8098751]
  20. Boccellari, A.A., Dilley, J.W., Yingling, C.D., Chambers, D.B., et al. Relationship of CD4 counts to neurophysiological function in HIV-1 infected homosexual men. Archives of Neurology. 1993b;50(5):517–521. [PubMed: 8098207]
  21. Booth, R.E., Watters, J.K., and Chitwood, D.D. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. American Journal of Public Health. 1993;83(8):1144–1148. [PMC free article: PMC1695160] [PubMed: 8342724]
  22. Bowen, G.S., Marconi, K., Kohn, S., Bailey, D.M., et al. First year of AIDS services delivery under Title I of the Ryan White CARE Act. Public Health Reports. 1992;107(5):491–499. [PMC free article: PMC1403689] [PubMed: 1410229]
  23. Boyer, P.J., Dillon, M., Navaie, M., Deveikis, A., et al. Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery. Journal of the American Medical Association. 1994;271(24):1925–1930. [PubMed: 7911164]
  24. Brickner, P.W., Torres, R.A., Barnes, M., Newman, R.G., et al. Recommendations for control and prevention of human immunodeficiency virus (HIV) infection in intravenous drug users. Annals of Internal Medicine. 1989;110(10):833–837. [PubMed: 2653157]
  25. Broder, S., Merigan, T.C., Jr., and Bolognesi, D., eds. Textbook of AIDS Medicine. Baltimore: Williams & Wilkins. 1994.
  26. Broers B., Morabia A., and Hirschel, B. A cohort study of drug users' compliance with zidovudine treatment. Archives of Internal Medicine. 1994;154(10):1121–1127. [PubMed: 8185425]
  27. Brown, B.S. AIDS and the provision of drug user treatment. International Journal of the Addictions. 1990-91; 25(12A):1503-1514 [PubMed: 1966836]
  28. Cabaj, R.P. AIDS and chemical dependency: special issues and treatment barriers for gay and bisexual men. Journal of Psychoactive Drugs. 1989;21(4):387–393. [PubMed: 2621509]
  29. Cameron, W., Sparti, P., Pietroski, N., et al. Rifabutin therapy for the prevention of MAC bacteremia in patients with AIDS and CD4 #200. Eighth International Conference on AIDS. Amsterdam, July. 1992.
  30. Center for Substance Abuse Treatment. Treatment for Alcohol and Other Drug Abuse. Opportunities for Collaboration. Technical Assistance Publication Series 11. DHHS Publication No. (SMA) 94-2075. Rockville, Maryland. 1994.
  31. Centers for Disease Control and Prevention. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morbidity and Mortality Weekly Report. 1994a; 43(RR-11):1-20 [PubMed: 7913986]
  32. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of mycobacterium tuberculosis in health-care facilities. Federal Register. 1994b;59(208):54242–54303. [PubMed: 10137654]
  33. Centers for Disease Control and Prevention. Zidovudine for the prevention of HIV transmission from mother to infant. Morbidity and Mortality Weekly Report. 1994c;43(16):285–287. [PubMed: 8159153]
  34. Centers for Disease Control and Prevention. National HIV seroprevalence survey, 1992. Washington, D.C., U.S. Government Printing Office. 1993a.
  35. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta: Centers for Disease Control and Prevention. 1993b.
  36. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. Morbidity and Mortality Weekly Report. 1993c; 42(RR-4):1-18 [PubMed: 8474421]
  37. Centers for Disease Control and Prevention. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Morbidity and Mortality Weekly Report. 1993d; 42(RR-9):14-20 [PubMed: 8393134]
  38. Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. Morbidity and Mortality Weekly Report. 1993e; 42(RR-14):1-102 [PubMed: 8145706]
  39. Centers for Disease Control and Prevention. Technical guidance on HIV counseling. Morbidity and Mortality Weekly Report. 1993f; 42(RR-2):11-17 [PubMed: 8382337]
  40. Centers for Disease Control and Prevention. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. Morbidity and Mortality Weekly Report. 1992; 41(RR-4):1-11 [PubMed: 1348843]
  41. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report. 1992a; 41(RR-17):1-19 [PubMed: 1361652]
  42. Centers for Disease Control and Prevention. National action plan to combat multidrug-resistant tuberculosis. Morbidity and Mortality Weekly Report. 1992b; 41(RR-11):5-48 [PubMed: 1640920]
  43. Centers for Disease Control and Prevention. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York 1988-1991. Morbidity and Mortality Weekly Report. 1991a;40(34):585–591. [PubMed: 1870559]
  44. Centers for Disease Control and Prevention. Purified protein derivative (PPD) Ctuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. Morbidity and Mortality Weekly Report. 1991b; 40(RR-5):27-32 [PubMed: 2034206]
  45. Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculous infection in high-risk populations. Recommendations of the Advisory Committee for the Elimination of Tuberculosis. Morbidity and Mortality Weekly Report. 1990; 39(RR-8):1-7 [PubMed: 2111876]
  46. Centers for Disease Control and Prevention. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET) Morbidity and Mortality Weekly Report. 1989; 38(14):236-238,243-250 [PubMed: 2494425]
  47. Centers for Disease Control and Prevention. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. Morbidity and Mortality Weekly Report. 1988; 37(24):377-382, 387-388 [PubMed: 2836717]
  48. Centers for Disease Control and Prevention. Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. Morbidity and Mortality Weekly Report. 1987a;36(31):509–515. [PubMed: 3112540]
  49. Centers for Disease Control and Prevention. Recommendations for prevention of HIV transmission in health-care settings. Morbidity and Mortality Weekly Report. 1987b; 36(Suppl. 2):1S-18S [PubMed: 3112554]
  50. Chaisson, R.E., Bacchetti, P., Osmond, D., Brodie, B., et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. Journal of the American Medical Association. 1989;261(4):561–565. [PubMed: 2909798]
  51. Chiasson, M.A., Stoneburner, R.L., Hildebrandt, D.S., Ewing, W.E., et al. Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack) AIDS. 1991;5(9):1121–1126. [PubMed: 1930775]
  52. Chirgwin, K., DeHovitz, J.A., Dillon, S., and McCormack, W.M. HIV infection, genital ulcer disease, and crack cocaine use among patients attending a clinic for sexually transmitted diseases. American Journal of Public Health . 1991;81(12):1576–1579. [PMC free article: PMC1405272] [PubMed: 1746652]
  53. Clark, S.J., Saag, M.S., Decker, W.D., Campbell-Hill, S., et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. New England Journal of Medicine . 1991;324(14):954–960. [PubMed: 1900576]
  54. Collier, A.C., Coombs, R.W., Fischl, M.A., Skolnik, P.R., et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Annals of Internal Medicine. 1993;119(8):786–793. [PubMed: 8379600]
  55. Cooper, D.A., Gatell, J.M., Kroon, S., Clumeck, N., et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. New England Journal of Medicine . 1993;329(5):297–303. [PubMed: 8100611]
  56. Cooper, J.R. Methadone treatment and acquired immunodeficiency syndrome. Journal of the American Medical Association . 1989;262(12):1664–1668. [PubMed: 2491420]
  57. Crane, L.R., Levine, D.P., Zervos, M.J., and Cummings, G. Bacteremia in narcotic addicts at the Detroit Medical Center. I. Microbiology, epidemiology, risk factors, and empiric therapy. Review of Infectious Diseases. 1986;8(3):364–373. [PubMed: 3636987]
  58. Daley, C.L., Small, P.M., Schecter, G.F., Schoolnik, G.K., et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. New England Journal of Medicine . 1992;326(4):231–235. [PubMed: 1345800]
  59. Dalton, H.L. AIDS in blackface. Daedalus. Journal of the American Academy of Arts and Sciences. 1989;118(3):205–227. [PubMed: 10318273]
  60. DeHovitz, J.A., and Sadovsky, R. Initial clinical assessment and management of HIV infection. Primary Care (Special issue: AIDS and HIV Infection in Office Practice) 1992;19(1):35–56. [PubMed: 1594702]
  61. DePhilippis, D., Metzger, D.S., Woody, G.E., and Navaline, H.A. Attitudes toward mandatory human immunodeficiency virus testing and contact tracing. A survey of intravenous drug users in treatment. Journal of Substance Abuse Treatment. 1992;9(1):39–42. [PubMed: 1593663]
  62. Des Jarlais, D.C., and Friedman, S.R. AIDS and the use of injected drugs. Scientific American. 1994a; February: pp. 82–88. [PubMed: 8108699]
  63. Des Jarlais, D.C., Friedman, S.R., Sotheran, J.L., Wenston, J., et al. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. Journal of the American Medical Association . 1994b;271(2):121–127. [PubMed: 8264066]
  64. Donahue, J.G., Nelson, K.E., Munoz, A., Vlahov, D., et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. American Journal of Epidemiology . 1991;134(10):1206–1211. [PubMed: 1720924]
  65. Donoghoe, M.C., Stimson, G.V., and Dolan, K.A. 1992. Syringe Exchange in England: An Overview.London: Tufnell Press.
  66. Drucker, E. Epidemic in the war zone: AIDS and community survival in New York City. International Journal of Health Services . 1990;20(4):601–615. [PubMed: 2265878]
  67. Esteban, J.I., Esteban, R., Vilamodiu, L., Lopez-Talavera, J.C., et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet. 1989;2(8658):294–297. [PubMed: 2569102]
  68. Farley, T.A., Cartter, M.L., Wassell, J.T., and Hadler, J.L. Predictors of outcome in methadone programs: effect of HIV counseling and testing. AIDS. 1992;6(1):115–121. [PubMed: 1543554]
  69. Fauci, A.A. Multifactorial value of HIV disease: implications for therapy. Science. 1993;262:1011-1018 [PubMed: 8235617]
  70. Fernandez, F. Psychopharmacological interventions in HIV infections. New Directions in Mental Health Services. 1990; 48:43-53 [PubMed: 2077389]
  71. Fernandez, F., Holmes, V.F., Levy, J.K., and Ruiz, P. Consultation-liaison psychiatry and HIV-related disorders. Hospital and Community Psychiatry. 1989;40(2):146–153. [PubMed: 2644161]
  72. Ferrando, S.J., and Batki, S.L. HIV-infected intravenous drug users in methadone maintenance treatment: clinical problems and their management. Journal of Psychoactive Drugs . 1991;23(2):217–224. [PubMed: 1662716]
  73. Fischl, M.A., Daikos, G.L., Uttamchandani, R.B., Poblete, R.B., et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Annals of Internal Medicine. 1992a;117(3):184–190. [PubMed: 1616212]
  74. Fischl, M.A., Uttamchandani, R.B., Daikos, G.L., Poblete, R.B., et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercule bacilli among patients with HIV infection. Annals of Internal Medicine. 1992b;117(3):177–183. [PubMed: 1616211]
  75. Fischl, M.A., Richman, D.D., Hansen, N., Collier, A.C., et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Annals of Internal Medicine. 1990;112(10):721–730. [PubMed: 1970466]
  76. Fischl, M.A., Richman, D.D., Grieco, M.H., Gottlieb, M.S., et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New England Journal of Medicine . 1987;317(4):185–191. [PubMed: 3299089]
  77. Folstein, M.F., Folstein, S.E., and McHugh, P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189–198. [PubMed: 1202204]
  78. Forstein, M. The neuropsychiatric aspects of HIV infection. Primary Care (Special issue: AIDS and HIV Infection in Office Practice) 1992;19(1):97–117. [PubMed: 1594705]
  79. Gallant, J.E., Moore, R.D., and Chaisson, R.E. Prophylaxis for opportunistic infections in patients with HIV infection. Annals of Internal Medicine. 1994; 120 (11):932-944 [PubMed: 8172439]
  80. Gerbert, B., Maguire, B.T., Bleeker, T., Coates, T.J., et al. Primary care physicians and AIDS. Attitudinal and structural barriers to care. Journal of the American Medical Association . 1991;266(20):2837–2842. [PubMed: 1942450]
  81. Girard, P.M., Landman, R., Gaudebout, C., Olivares, R., et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prohphylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. New England Journal of Medicine . 1993;328(21):1514–1520. [PubMed: 8479488]
  82. Glassroth, J., Jordan, M., Wallace, J.M., Kvale, P.A., et al. Use of preventive interventions by persons infected with type-1 human immunodeficiency virus (HIV-1). The Pulmonary Complications of HIV Study Group. American Journal of Preventive Medicine . 1994;10(5):259–266. [PubMed: 7848668]
  83. Gorbach, S.L., Knox, T.A., and Roubenoff, R. Interactions between nutrition and infection with human immunodeficiency virus. Nutrition Review. 1993;51(8):226–234. [PubMed: 8302492]
  84. Graham, N.M., Zeger, S.L., Park, L.P., Vermund, S.H., et al. The effects on survival of early treatment of human immunodeficiency virus infection. New England Journal of Medicine . 1992;326(16):1037–1042. [PubMed: 1347907]
  85. Graham, N.M., Zeger, S.L., Park, L.P., Phair, J.P., et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. Lancet. 1991;338(8762):265–269. [PubMed: 1677108]
  86. Hahn, R.A., Onorato, I.M., Jones, T.S., and Dougherty, J. Prevalence of HIV infection among intravenous drug users in the United States. Journal of the American Medical Association . 1989;261(18):2677–2684. [PubMed: 2651732]
  87. Hamilton, J.D., Hartigan, P.M., Simberkoff, M.S., Day, P.L., et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. New England Journal of Medicine . 1992b;326(7):437–443. [PubMed: 1346337]
  88. Hartel, D.M., Schoenbaum, E.E., Selwyn, P.A., Kline, J., et al. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. American Journal of Public Health . 1995;85(1):83–88. [PMC free article: PMC1615273] [PubMed: 7832267]
  89. Hartel, D.M., Selwyn, P.A., Schoenbaum, E.E., et al. Methadone maintenance treatment and reduced risk of AIDS and AIDS-specific mortality in intravenous drug users (abstract no. 8546) Fourth International Conference on AIDS. Stockholm, Sweden, June. 1988.
  90. Hartigan, P.M., Hamilton, J.D., and Simberkoff, M.S. Early zidovudine and survival in HIV infection. The Veterans Affairs AIDS Cooperative Studies Group (letter, comment) New England Journal of Medicine . 1992; 327(11):814-815; discussion 815-816 [PubMed: 1501668]
  91. Hecht, F.M., and Soloway, B. HIV infection: a primary care approach. Reprints from AIDS Clinical Care Newsletter. Boston: Massachusetts Medical Society. 1992 and 1993.
  92. Higgins, D.L., Galavotti, C., O'Reilly, K.R., Schnell, D.J., et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. Journal of the American Medical Association . 1991;266(17):2419–2429. [PubMed: 1920748]
  93. Hoover, D.R., Saah, A.J., Bacellar, H., Phair, J., et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. New England Journal of Medicine . 1993;329(26):1922–1926. [PubMed: 7902536]
  94. Hughes, C.P., Berg, L., Danziger, W.L., Cohen, L.A., et al. A new clinical scale for the staging of dementia. British Journal of Psychiatry . 1982; 140:566-572 [PubMed: 7104545]
  95. Iguchi, M.Y., Watters, J., Biernacki, P., McCoy, C.B., et al. Update: reducing HIV transmission in intravenous-drug users not in drug treatment - United States. Morbidity and Mortality Weekly Report. 1990; 39(31):529, 535-538 [PubMed: 2115973]
  96. Jewett, J.F., and Hecht, F.M. Preventive health care for adults with HIV infection. Journal of the American Medical Association . 1993;269(9):1144–1153. [PubMed: 8433470]
  97. Jones, P., Hamilton, P.J., Oxley, A., Codd, A., et al. Anti-HTLV-III positive laboratory reagents (letter) Lancet. 1985;1(8443):1458–1459. [PubMed: 2861405]
  98. Kanof, P.D., Aronson, M.J., and Ness, R. Organic mood syndrome associated with detoxification from methadone maintenance. American Journal of Psychiatry . 1993;150(3):423–428. [PubMed: 8434657]
  99. Karan, L.D. Primary care for AIDS and chemical dependence. Western Journal of Medicine. 1990;152(5):538–542. [PMC free article: PMC1002407] [PubMed: 2190422]
  100. Khabazz, R.F., Khabbaz, R.F., Onorato, I.M., Cannon, R.O., Hartley, T.M., et al. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. New England Journal of Medicine. 1992;326(6):375–380. [PubMed: 1729620]
  101. Kosten, T.R. Client issues in drug abuse treatment: addressing multiple drug use. In: Pickens, R.W., Leukefeld, C.G., and Schuster, C.R., eds. Improving Drug Abuse Treatment. NIDA Research Monograph 106. DHHS Publication No. (ADM) 91-1754. Rockville, Maryland: National Institute on Drug Abuse. 1991. pp. pp. 136–151.
  102. Kreek, M.J., Garfield, J.W., Gutjahr, C.L., and Giusti, L.M. Rifampin-induced methadone withdrawal. New England Journal of Medicine . 1976;294(20):1104–1106. [PubMed: 1256526]
  103. Krogsgaard, K., Lindhardt, B.O., Nielson, J.O., Andersson, P., et al. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology. 1987;7(1):37–41. [PubMed: 3643160]
  104. Lampinen, T.M. Cost-effectiveness of drug abuse treatment for primary prevention of acquired immunodeficiency syndrome: epidemiologic considerations. In: Cartwright, W.S., and Kaple, J.M., eds. Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug Treatment. NIDA Research Monograph 113. DHHS Publication No. (ADM) 91-1823. Rockville, Maryland: National Institute on Drug Abuse. 1991. pp. pp. 114–128.
  105. Legal Action Center. Confidentiality: A Guide to the Federal Laws and Regulations. New York: Legal Action Center. 1991.
  106. Libman, H., Samet, J.H., Freedberg, K.A., Jain, M., et al. Referral to the community for continuing medical care of newly identified patients with human immunodeficiency virus infection: experience from a diagnostic evaluation unit. Clinical Research. 1992; 40:586A
  107. Libman, H., and Witzburg, R.A., eds. 1993. HIV Infection: A Clinical Manual.2nd ed. Boston: Little, Brown.
  108. Lowinson, J.H., Marion, I.J., Joseph, H., and Dole, V.P. Methadone maintenance. In Lowinson, J.H., Ruiz, P., and Millman, R.B., eds. Substance Abuse: A Comprehensive Textbook. Baltimore: Williams & Wilkins. 1992. pp. pp. 550–561.
  109. Lundgren, J.D., Phillips, A.N., Pedersen, C., Clumeck, N., et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. Journal of the American Medical Association . 1994;271(14):1088–1092. [PubMed: 8151850]
  110. Lurie, P., Reingold, A.L., Bowser, B.J., et al. The Public Health Impact of Needle Exchange Programs in the United States and Abroad: Summary, Conclusions, and Recommendations. Centers for Disease Control and Prevention, October. 1993.
  111. Lyketsos, C.G., Hanson, A.L., Fishman, M., Rosenblatt, A., et al. Manic syndrome early and late in the course of HIV. American Journal of Psychiatry . 1993;150(2):326–327. [PubMed: 8422087]
  112. Margolick, J.B., Munoz, A., Vlahov, D., Solomon, L., et al. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. Journal of the American Medical Association . 1992;267(12):1631–1636. [PubMed: 1347321]
  113. Marin, G. AIDS prevention among Hispanics: needs, risk behaviors, and cultural values. Public Health Reports. 1989;104(5):411–415. [PMC free article: PMC1579967] [PubMed: 2508169]
  114. Massing, M. The rehabbing of America. New York Times Review of Books. January 24, 1993. pp. pp. 10–12.
  115. McLellan, A.T., Arndt, I.O., Metzger, D.S., Woody, G.E., et al. The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association . 1993;269(15):1953–1959. [PubMed: 8385230]
  116. Metzger, D.S., Woody, G.E., McLellan, A.T., O'Brien, C.P., et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndrome . 1993;6(9):1049–1056. [PubMed: 8340896]
  117. Minnesota Department of Human Services. HIV-1 Guidelines for Chemical Dependency Treatment and Care Programs in Minnesota. (updated 1992). St. Paul: Minnesota Department of Human Services. 1992.
  118. Mirin, S.M., Weiss, R.D., Michael, J., and Griffin, M.L. Psychopathology in substance abusers: diagnosis and treatment. American Journal of Drug and Alcohol Abuse . 1988;14(2):139–157. [PubMed: 3052036]
  119. Moore, R.D., Hidalgo, J., Sugland, B.W., and Chaisson, R.E. Zidovudine and the natural history of the acquired immunodeficiency syndrome. New England Journal of Medicine . 1991;324(20):1412–1416. [PubMed: 2020297]
  120. Moreno, S., Baraia-Etxaburu, J., Bouza, E., Parras, F., et al. Risk for developing tuberculosis among anergic patients infected with HIV. Annals of Internal Medicine . 1993;119(3):194–198. [PubMed: 8100693]
  121. Moss, A.R., and Bacchetti, P. Natural history of HIV infection (published erratum appears in AIDS 3(7): following page A100) AIDS. 1989;3(2):55–61. [PubMed: 2496720]
  122. Moss, A.R., Vranizan, K., Gorter, R., Bacchetti, P., et al. HIV seroconversion in intravenous drug users in San Francisco; 1985-1990. AIDS. 1994;8(2):223–231. [PubMed: 8043227]
  123. Musher, D.M., Hamill, R.J., and Baughn, R.E. Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. Annals of Internal Medicine. 1990;113(11):872–881. [PubMed: 2240901]
  124. National AIDS Network. Dually diagnosed present multiple challenges to service providers. NAN Multi-Cultural Notes on AIDS Education and Service. 1990;3(2):1–7.
  125. National Commission on AIDS, Working Group on Social/Human Issues 1991.
  126. National Institute of Allergy and Infectious Diseases. State-of-the-art conference on azidothymidine therapy for early HIV infection. American Journal of Medicine . 1990;89(3):335–344. [PubMed: 2203263]
  127. New York State Department of Health, AIDS Institute. Protocols for the Medical Care of HIV Infection. Albany: Department of Health. 1992.
  128. Nightingale, S.D., Cameron, D.W., Gordin, F.M., Sullam, P.M., et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infections in AIDS. New England Journal of Medicine . 1993;329(12):828–833. [PubMed: 8179648]
  129. Northfelt, D.W. Evaluation and treatment of later manifestations of HIV infection. Primary Care (Special issue: AIDS and HIV Infection in Office Practice) 1992;19(1):57–85. [PubMed: 1594703]
  130. Novick, D.M., and Ness, G.L. Abuse of antibiotics by abusers of parenteral heroin or cocaine. Southern Medical Journal . 1984;77(3):302–303. [PubMed: 6701614]
  131. O'Brien, T.R., George, J.R., and Holmberg, S.D. Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications. Journal of the American Medical Association . 1992;267(20):2775–2779. [PubMed: 1578597]
  132. Occupational Safety and Health Administration. Controlling Occupational Exposure to Bloodborne Pathogens in Dentistry. Washington, D.C.: OSHA. 1992.
  133. O'Connor, P.G., Selwyn, P.A., and Schottenfeld, R.S. Medical care for injection-drug users with human immunodeficiency virus infection. New England Journal of Medicine . 1994;331(7):450–459. [PubMed: 8035842]
  134. O'Connor, P.G., Molde, S., Henry, S., Shockcor, W.T., et al. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. American Journal of Medicine . 1992;93(4):382–386. [PubMed: 1415300]
  135. O'Dowd, M.A., Natali, C., Orr, D., and McKegney, F.P. Characteristics of patients attending an HIV-related psychiatric clinic. Hospital and Community Psychiatry. 1991;42(6):615–619. [PubMed: 1864572]
  136. Office of Technology Assessment. The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection. Washington, D.C.: U.S. Government Printing Office. 1990.
  137. Onorato, I.M., and Markowitz, L.E. 1992. Immunizations, vaccine-preventable diseases, and HIV infection; In AIDS and other manifestations of HIV infection. 2nd ed. New York: Raven Press; pp. pp. 671–681.
  138. Orlander, J.D., Samet, J.H., Kazis, L., Freedberg, K.A., et al. Improving medical residents' attitudes toward HIV-infected persons through training in an HIV staging and triage clinic. Academic Medicine. 1994;69(12):1001–1003. [PubMed: 7999177]
  139. Osmond, D., Charlebois, E., Lang, W., Shiboski, S., et al. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983-1993. Journal of the American Medical Association . 1994;271(14):1083–1087. [PubMed: 7908703]
  140. Page, J.B., Lai, S.H., Chitwood, D.D., Klimas, N.G., et al. HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet. 1990;335(8703):1439–1441. [PubMed: 1972217]
  141. Page, Y., Tardy, B., Zeni, F., Comtet, C., et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet. 1991;337(8744):774–776. [PubMed: 1672401]
  142. Pantaleo, G., Graziosi, C., Demarest, J.F., Butini, L., et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362(6418):355–358. [PubMed: 8455722]
  143. Perez-Arce, P., Carr, K.D., and Sorensen, J.L. Cultural issues in an outpatient program for stimulant abusers. Journal of Psychoactive Drugs . 1993;25(1):35–44. [PubMed: 8097765]
  144. Piette, J.D., Fleishman, J.A., Stein, M.D., Mor, V., et al. Perceived needs and unmet needs for formal services among people with HIV disease. Journal of Community Health. 1993;18(1):11–23. [PubMed: 8450090]
  145. Price, R.W., and Brew, B.J. The AIDS dementia complex. Journal of Infectious Diseases . 1988;158(5):1079–1083. [PubMed: 3053922]
  146. Pohl, M. Neurocognitive impairment in alcoholics: review and comparison with cognitive impairment due to AIDS. (Issue title: AIDS and Substance Abuse.) Advances in Alcohol and Substance Abuse. 1987; 7(2)107-116 [PubMed: 3329445]
  147. Rakower, D., and Galvin, T.A. Nutrition in HIV infection. New York State Department of Health, AIDS Institute. 3(4):29. 1989.
  148. Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results for the Epidemiological Catchment Area (ECA) Study. Journal of the American Medical Association . 1990;264(19):2511–2518. [PubMed: 2232018]
  149. Ross, H.E., Glaser, F.B., and Germanson, T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Archives of General Psychiatry. 1988;45(11):1023–1031. [PubMed: 3263100]
  150. Rutherford, G.W., Lifson, A.R., Hessol, N.A., Darrow, W.W., et al. Course of HIV-1 infection in a cohort of homosexual and bisexual men: an 11 year follow up study. British Medical Journal . 1990;301(6762):1183–1188. [PMC free article: PMC1664363] [PubMed: 2261554]
  151. Saag, M.S. The natural history of HIV-1 infection. In: Broder, S., Merigan, T.C., and Bolognesi, D., eds. Textbook of AIDS Medicine. Baltimore: Williams & Wilkins. 1994a. pp. pp. 45–53.
  152. Saag, M.S. What to do when zidovudine fails (editorial; comment) New England Journal of Medicine . 1994b;330(10):706–707. [PubMed: 8107721]
  153. Samet, J.H., Stein, M.D., and O'Connor, P.G. Models of medical care of HIV-infected drug users. Archives of Internal Medicine. in press
  154. Samet, J.H., Libman, H., LaBelle, C., et al. A model clinic for the initial evaluation and establishment of primary care for HIV-infected persons. unpublished study. 1994.
  155. Samet, J.H., Libman, H., Steger, K.A., Dhawan, R.K., et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. American Journal of Medicine . 1992a;92(5):495–502. [PubMed: 1580296]
  156. Samet, J.H., Retondo, M.J., Freedberg, K.A., Stein, M.D., et al. Factors associated with late initial presentation to primary medical care for human immunodeficiency virus-infected persons. Clinical Research. 1992b; 40:562A
  157. Samet, J.H., Libman, H., Freedberg, K.A., and Craven, D.E. Staging and triage of persons infected with human immunodeficiency virus at a municipal hospital. Clinical Research. 1991; 39:608A
  158. Samet, J.H., Libman, H., LaBelle, C., Steger K., et al. A model clinic for the initial evaluation and establishment of primary care for HIV-infected persons. Submitted for publication 1994.
  159. Samuels, J.E., Hendrix, J., Hilton, M., Marantz, P.R., et al. Zidovudine therapy in an inner city population. Journal of Acquired Immune Deficiency Syndrome. 1990;3(9):877–883. [PubMed: 2384864]
  160. Sande, M.A., Carpenter, C.C., Cobbs, C.G., Holmes, K.K., et al. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. Journal of the American Medical Association . 1993;270(21):2583–2589. [PubMed: 7901434]
  161. Sawyer, R.C., Brown, K.S., et al. Evaluation of a possible pharmacologic interaction between rifabutin and methadone in HIV-seropositive injecting drug users (PO-B30-2197) Ninth International Conference on AIDS. Berlin. 1993.
  162. Schilling, R.F., Schinke, S.P., Nichols, S.E., Zayas, L.H., et al. Developing strategies for AIDS prevention research with black and Hispanic drug users. Public Health Reports. 1989;104(1):2–11. [PMC free article: PMC1580274] [PubMed: 2493660]
  163. Schleifer, S.J., Keller, S.E., Lombardo, J.M., Franklin, J.E., LaFarge, S., and Miller, S.I. HIV-1 antibody reactivity in inner-city alcoholics (letter) Journal of the American Medical Association . 1993. 1989; 262:2680-2681 [PubMed: 2810595]
  164. Schneider, M.M., Hoepelman, A.I., Eeftinck Schattenkerk, J.K., Nielsen, T.L., et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. New England Journal of Medicine . 1992;327(26):1836–1841. [PubMed: 1360145]
  165. Schoenbaum, E.E., Hartel, D., Selwyn, P.A., Klein, R.S., et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. New England Journal of Medicine . 1989;321(13):874–879. [PubMed: 2770823]
  166. Schwartz, E.L., Brechbuhl, A.B., Kahl, P., Miller, M.A., et al. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. Journal of Acquired Immune Deficiency Syndrome . 1992;5(6):619–626. [PubMed: 1588496]
  167. Selwyn, P.A., Budner, N.S., Wasserman, W.C., and Arno, P.S. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Reports. 1993;108(4):492–500. [PMC free article: PMC1403415] [PubMed: 8393579]
  168. Selwyn, P.A., and O'Connor, P.G. Diagnosis and treatment of substance users with HIV infection. Primary Care (Special issue: AIDS and HIV Infection in Office Practice) 1992;19(1):119–156. [PubMed: 1594693]
  169. Selwyn, P.A., Alcabes, P., Hartel, D., Buono, D., et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection (published erratum appears in New England Journal of Medicine 328 (9):671) New England Journal of Medicine . 1992a;327(24):1697–1703. [PubMed: 1359411]
  170. Selwyn, P.A., Sckell, B.M., Alcabes, P., Friedland, G.H., et al. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy (published erratum appears in Journal of the American Medical Association 268(24):3434, see comments, 1992) Journal of the American Medical Association . 1992b;268(4):504–509. [PubMed: 1619742]
  171. Selwyn, P.A., Feingold, A.R., Iezza, A., Satyadeo, M., et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Annals of Internal Medicine. 1989;111(9):761–763. [PubMed: 2802435]
  172. Sorenson, J.L., and Batki, S.L. Management of psychosocial sequelae of HIV infections among drug users. In: Lowinson, J.H., Ruiz, P., and Millman, R.R., eds. Substance abuse: A Comprehensive Textbook. Baltimore: Williams & Wilkins. 1992.
  173. Spruance, S.L., Pavia, A.T., Peterson, D., Berry, A., et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb A1454-010 Study Group. Annals of Internal Medicine. 1994;120(5):360–368. [PubMed: 7905722]
  174. Stein, D.S., Graham, N.M., Park, L.P., Hoover, D.R., et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Annals of Internal Medicine. 1994;121(2):100–108. [PubMed: 8017721]
  175. Stein, M.D., Samet, J.H., and O'Connor, P.G. The linkage of primary care services with substance abuse treatment: new opportunities for academic generalists. Journal of General Internal Medicine . 1993;8(2):106–107. [PubMed: 8382743]
  176. Stimmel, B., Vernace, S., and Schaffner, F. Hepatitis B surface antigen and antibody. A prospective study in asymptomatic drug abusers. Journal of the American Medical Association . 1975;234(11):1135–1138. [PubMed: 810605]
  177. Thomas, S.B., and Quinn, S.C. The Tuskegee Syphilis Study, 1932 to 1972: implications for HIV education and AIDS risk education programs in the black community. American Journal of Public Health . 1991;81(11):1498–1505. [PMC free article: PMC1405662] [PubMed: 1951814]
  178. Tong, T.G., Pond, S.M., Kreek, M.J., Jaffery, N.F., et al. Phenytoin-induced methadone withdrawal. Annals of Internal Medicine. 1981;94(3):349–351. [PubMed: 7224382]
  179. Umbricht-Schneiter, A., Ginn, D.H., Pabst, K.M., and Bigelow, G.E. Providing medical care to methadone clinic patients: referral vs. on-site care. American Journal of Public Health . 1994;84(2):207–210. [PMC free article: PMC1615007] [PubMed: 8296941]
  180. Volberding, P.A., Lagakos, S.W., Koch, M.A., Pettinelli, C., et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. New England Journal of Medicine . 1990;322(14):941–949. [PubMed: 1969115]
  181. Ward, J.W., Bush, T.J., Perkins, H.A., Lieb, L.E., et al. The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. New England Journal of Medicine . 1989;321(14):947–952. [PubMed: 2779617]
  182. Weiss, S. H. Links between cocaine and retroviral infection. Journal of the American Medical Association . 1989;261(4):607–609. [PubMed: 2535879]
  183. Wiegand, M., Moller, A.A., Schreiber, W., Krieg, J.C., et al. Alterations of nocturnal sleep in patients with HIV infection. Acta Neurologica Scandinavica. 1991;83(2):141–142. [PubMed: 2017899]
  184. Youle, M.S., Gazzard, B.G., Johnson, M.A., Cooper, D.A., et al. Effects of high-dose oral acyclovir on herpes virus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. European-Australian Acyclovir Study Group (published erratum appears in AIDS 8(6): following 859) AIDS. 1994;8(5):641–649. [PubMed: 8060544]

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...